Panelists discuss how to overcome barriers to comprehensive molecular testing and how to prioritize treatment when ALK+ non–small cell lung cancer (NSCLC) coexists with other actionable biomarkers.
Molecular Testing and Biomarker Considerations
Key Themes:
Notable Insights:
Dr Lovly addressed treatment prioritization in patients with both ALK+ status and other biomarkers (eg, PD-L1 >1%)
Echocardiographic Assessment Shows Promise as Risk Predictor in PAH
August 29th 2025Close to 40% of patients with right heart failure and pulmonary arterial hypertension (PAH) who remain critically ill and require admittance to the intensive care unit die within 1 year of that hospitalization.
Read More